Evidence map›Paper›PMID 23783032›Full record

ArticleMolecular biology of the cell2013

The PI3K/Akt1 pathway enhances steady-state levels of FANCL.

Kim-Hien T Dao, Michael D Rotelli, Brieanna R Brown, Jane E Yates, Juha Rantala, Cristina Tognon, Jeffrey W Tyner, Brian J Druker, Grover C Bagby

Abstract read
In one paragraph

Article in Molecular biology of the cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. FANCL supports Parkin-mediated mitophagy in a ubiquitin ligase-independent manner.Biochimica et biophysica acta. Molecular basis of disease · 2022
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kim-Hien T DaoKnight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA. daok@ohsu.edu
Michael D Rotelli
Brieanna R Brown
Jane E Yates
Juha Rantala
Cristina Tognon
Jeffrey W Tyner
Brian J Druker
Grover C Bagby
Oregon Health & Science University · USHoward Hughes Medical Institute · US

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Xenograft CoreP01HL048546 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SHIMAMURA, AKIKO · 1994 to 2020
$36.4M
Oregon Clinical and Translational Research InstituteUL1TR000128 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLISON, DAVID H · 2012 to 2015
$28.7M
Fanconi Anemia stem cells allow molecular characterization of acute leukemiaR01CA138237 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI BAGBY, GROVER CARLTON, CLAPP, DAVID W · 2008 to 2012
$1.9M
ROR1 as a Therapeutic Target in Acute Lymphoblastic LeukemiaR00CA151457 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI TYNER, JEFFREY WALLACE · 2012 to 2014
$723k
Beta-catenin is a molecular target of the Fanconi anemia core complexK08HL111280 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DAO, KIM-HIEN T · 2012 to 2016
$671k
Howard Hughes Medical InstituteNCATS NIH HHS UL1 TR000128NCI NIH HHS 1R01CA138237NCI NIH HHS 4R00CA151457NCI NIH HHS P30 CA069533NCI NIH HHS R00 CA151457NCI NIH HHS R01 CA138237NHLBI NIH HHS 1K08HL111280NHLBI NIH HHS 5P01 HL048546NHLBI NIH HHS K08 HL111280NHLBI NIH HHS P01 HL048546
6 · The paper itself

Abstract

Fanconi anemia hematopoietic stem cells display poor self-renewal capacity when subjected to a variety of cellular stress. This phenotype raises the question of whether the Fanconi anemia proteins are stabilized or recruited as part of a stress response and protect against stem cell loss. Here we provide evidence that FANCL, the E3 ubiquitin ligase of the Fanconi anemia pathway, is constitutively targeted for degradation by the proteasome. We confirm biochemically that FANCL is polyubiquitinated with Lys-48-linked chains. Evaluation of a series of N-terminal-deletion mutants showed that FANCL's E2-like fold may direct ubiquitination. In addition, our studies showed that FANCL is stabilized in a complex with axin1 when glycogen synthase kinase-3β is overexpressed. This result leads us to investigate the potential regulation of FANCL by upstream signaling pathways known to regulate glycogen synthase kinase-3β. We report that constitutively active, myristoylated-Akt increases FANCL protein level by reducing polyubiquitination of FANCL. Two-dimensional PAGE analysis shows that acidic forms of FANCL, some of which are phospho-FANCL, are not subject to polyubiquitination. These results indicate that a signal transduction pathway involved in self-renewal and survival of hematopoietic stem cells also functions to stabilize FANCL and suggests that FANCL participates directly in support of stem cell function.

Indexed as

Axin ProteinCell LineEnzyme ActivationFanconi AnemiaFanconi Anemia Complementation Group L ProteinGene ExpressionGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHEK293 CellsHeLa CellsHematopoietic Stem CellsHumansPhosphatidylinositol 3-KinasesProteasome Endopeptidase ComplexProtein FoldingProto-Oncogene Proteins c-aktAKT1 protein, humanAXIN1 protein, humanAxin ProteinFANCL protein, humanFanconi Anemia Complementation Group L ProteinGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGSK3B protein, humanPhosphatidylinositol 3-KinasesProteasome Endopeptidase ComplexProto-Oncogene Proteins c-aktRNA, Small Interfering

Identifiers

PMID23783032
PMCPMC3744951
OpenAlexW2016801118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.